Efficient RNAi-induced Protein Knockdown in Somatic Cells Using Diced or Chemically Produced Small Interfering RNAs (siRNA)

Background: RNA interference (RNAi) is a post-transcriptional gene silencing process in which double-stranded RNA (dsRNA) directs the degradation of a specifi c corresponding target mRNA. The mediators of this process are small dsRNAs of approximately 21 to 23 bp in length, called small interfering RNAs (siRNAs), which can be prepared in vitro and used to direct the degradation of specifi c mRNAs inside cells. Hence, siRNAs represent a powerful tool to study and control gene and cell function. Rapid progress has been made in the use of siRNA as a means to attenuate the expression of any protein for which the cDNA sequence is known. Individual siRNAs can be chemically synthesized, in vitro-transcribed, or expressed in cells from siRNA expression vectors. However, screening for the most effi cient siRNAs for post-transcriptional gene silencing in cells in culture is a laborious and expensive process. In this study, the effectiveness of two siRNA production strategies for the attenuation of abundant proteins for DNA repair were compared in human cells: (a) the in vitro production of siRNA mixtures by the Dicer enzyme (Diced siRNAs); and (b) the chemical synthesis of very specifi c and unique siRNA sequences (Stealth RNaiTM). Dicing” to create mixtures of siRNAs. The Diced fragments of siRNA for each gene sequence were pooled and stored at -80o C. Alternatively, chemically synthesized Stealth siRNAs were designed and generated to match two very specifi c gene sequence regions for each target gene of interest (Ku70 and Xrcc4). HCT116 cells were plated at 30% confl uence in 24- or 6-well culture plates. The next day, cells were transfected by lipofection with either Diced or Stealth siRNAs for Ku70 or Xrcc4, in duplicate, at various doses, with blank and sham transfections used as controls. Cells were harvested at 0, 24, 48, 72 and 96 h post-transfection for protein determination. The knockdown of specifi c targeted gene products was quantifi ed by Western blot using GAPDH as control. Transfection of gene-specifi c siRNA to either Ku70 or Xrcc4 with both Diced and Stealth siRNAs resulted in a down regulation of the targeted proteins to approximately 10 to 20% of control levels 48 h after transfection, with recovery to pre-treatment levels by 96 h. Discussion: By transfecting cells with Diced or chemically synthesized Stealth siRNAs, Ku70 and Xrcc4, two highly expressed proteins in cells, were effectively attenuated, demonstrating the great potential for the use of both siRNA production strategies as tools to perform loss of function experiments in mammalian cells. In fact, down-regulation of Ku70 and Xrcc4 has been shown to reduce the activity of the non-homologous end joining DNA pathway, a very desirable approach for the use of homologous recombination technology for gene targeting or knockout studies. Stealth RNAiTM was developed to achieve high specifi city and greater stability when compared with mixtures of enzymatically-produced (Diced) siRNA fragments. In this study, both siRNA approaches inhibited the expression of Ku70 and Xrcc4 gene products, with no detectable toxic effects to the cells in culture. However, similar knockdown effects using Diced siRNAs were only attained at concentrations 10-fold higher than with Stealth siRNAs. The application of RNAi technology will expand and continue to provide new insights into gene regulation and as potential applications for new therapies, transgenic animal production and basic research.

[1]  Zhihong Zhang,et al.  Cell‐selective gene silencing in prostate cancer LNCap cells using prostate‐specific membrane antigen promoter and enhancer in vitro and in vivo , 2012, Cell biology international.

[2]  A. Belayew,et al.  On-chip microelectrophoresis for the study of in vitro nonhomologous end-joining DNA double-strand break repair. , 2012, Analytical biochemistry.

[3]  Yuan Luo,et al.  The SID-1 double-stranded RNA transporter is not required for systemic RNAi in the migratory locust , 2012, RNA biology.

[4]  Karol Kozak,et al.  Z’ Factor including siRNA design quality parameter in RNAi screening experiments , 2012, RNA biology.

[5]  Takashi Kohno,et al.  Essential Factors for Incompatible DNA End Joining at Chromosomal DNA Double Strand Breaks In Vivo , 2011, PloS one.

[6]  May P. Xiong,et al.  Non-cell-autonomous RNA interference in mammalian cells: Implications for in vivo cell-based RNAi delivery , 2011, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.

[7]  M. Peoples,et al.  Production of Transgenic Calves Expressing an shRNA Targeting Myostatin , 2011, Molecular reproduction and development.

[8]  N. Curtin,et al.  Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K , 2011, Molecular Cancer Therapeutics.

[9]  C. Hsieh,et al.  Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy , 2011, The Prostate.

[10]  M. Zamora,et al.  RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. , 2011, American journal of respiratory and critical care medicine.

[11]  E. Kass,et al.  Collaboration and competition between DNA double‐strand break repair pathways , 2010, FEBS letters.

[12]  Robert Langer,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[13]  J. Murray,et al.  Increased Gene Targeting in Ku70 and Xrcc4 Transiently Deficient Human Somatic Cells , 2009, Molecular biotechnology.

[14]  John J. Rossi,et al.  The promises and pitfalls of RNA-interference-based therapeutics , 2009, Nature.

[15]  A. Aguilera,et al.  DNA Repair in Mammalian Cells , 2009, Cellular and Molecular Life Sciences.

[16]  T. Honda,et al.  Tumor growth inhibition by synthetic and expressed siRNA targeting focal adhesion kinase. , 2008, International journal of oncology.

[17]  E. Hendrickson,et al.  Ku70, an essential gene, modulates the frequency of rAAV-mediated gene targeting in human somatic cells , 2008, Proceedings of the National Academy of Sciences.

[18]  S. Beaucage Solid-phase synthesis of siRNA oligonucleotides. , 2008, Current opinion in drug discovery & development.

[19]  E. Pastwa,et al.  Non-homologous DNA end joining in anticancer therapy. , 2007, Current cancer drug targets.

[20]  J. Murray,et al.  Transient depletion of Ku70 and Xrcc4 by RNAi as a means to manipulate the non-homologous end-joining pathway. , 2007, Journal of biotechnology.

[21]  P. Opolon,et al.  Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. , 2006, Human gene therapy.

[22]  R. E. Foster,et al.  Monoubiquitination of the nonhomologous end joining protein XRCC4. , 2006, Biochemical and biophysical research communications.

[23]  Anastasia Khvorova,et al.  3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.

[24]  J. Puymirat,et al.  RNA based gene therapy for dominantly inherited diseases. , 2006, Current gene therapy.

[25]  T. Sakurai,et al.  Blockade of bulky lymphoma‐associated CD55 expression by RNA interference overcomes resistance to complement‐dependent cytotoxicity with rituximab , 2006, Cancer science.

[26]  Assam El-Osta,et al.  RNA interference and potential therapeutic applications of short interfering RNAs , 2005, Cancer Gene Therapy.

[27]  Terran Lane,et al.  A computational study of off-target effects of RNA interference , 2005, Nucleic acids research.

[28]  J. Kaplan,et al.  Stable Plasma Membrane Levels of hCTR1 Mediate Cellular Copper Uptake* , 2005, Journal of Biological Chemistry.

[29]  H. Soifer,et al.  A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon , 2005, Nucleic acids research.

[30]  D. V. van Gent,et al.  The mechanism of non-homologous end-joining: a synopsis of synapsis. , 2004, DNA repair.

[31]  B. Williams,et al.  RNA interference and double-stranded-RNA-activated pathways. , 2004, Biochemical Society transactions.

[32]  M. Wood,et al.  RNA interference: from model organisms towards therapy for neural and neuromuscular disorders. , 2004, Human molecular genetics.

[33]  Y. Li,et al.  Genome-wide expression profiling of RNA interference of hepatitis B virus gene expression and replication , 2004, Cellular and Molecular Life Sciences CMLS.

[34]  Tyra G. Wolfsberg,et al.  Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Wood,et al.  Survival of motor neuron gene downregulation by RNAi: towards a cell culture model of spinal muscular atrophy. , 2004, Brain research. Molecular brain research.

[36]  John J Rossi,et al.  Approaches for the sequence-specific knockdown of mRNA , 2003, Nature Biotechnology.

[37]  K. Valerie,et al.  Regulation and mechanisms of mammalian double-strand break repair , 2003, Oncogene.

[38]  S. Fesik,et al.  Specificity of short interfering RNA determined through gene expression signatures , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. Southern,et al.  A simple and cost-effective method for producing small interfering RNAs with high efficacy. , 2003, Nucleic acids research.

[40]  Joshua T. Jones,et al.  Recombinant Dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing , 2003, Nature Biotechnology.

[41]  F. Buchholz,et al.  Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Stacy L DeRuiter,et al.  RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Schultz,et al.  RNAi in mouse oocytes and preimplantation embryos: effectiveness of hairpin dsRNA. , 2001, Biochemical and biophysical research communications.

[44]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[45]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[46]  A. Joyner,et al.  Inactivation of the mouse Huntington's disease gene homolog Hdh. , 1995, Science.

[47]  M. Satoh,et al.  Role of free p70 (Ku) subunit in posttranslational stabilization of newly synthesized p80 during DNA-dependent protein kinase assembly. , 1995, European journal of cell biology.

[48]  P. Jeggo,et al.  X-ray-sensitive mutants of Chinese hamster ovary cell line. Isolation and cross-sensitivity to other DNA-damaging agents. , 1983, Mutation research.

[49]  P. Linsley,et al.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.